Anika Therapeutics (ANIK) Non-Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Non-Current Assets data on file, last reported at $85.8 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 2.58% year-over-year to $85.8 million in Q1 2026; TTM through Mar 2026 was $349.0 million, a 8.2% decrease from a year earlier, with the FY2025 full-year figure at $86.9 million, down 2.44% from the prior year.
• Non-Current Assets for Q1 2026 stood at $85.8 million, down from $86.9 million in the prior quarter.
• Over the last five years, Non-Current Assets for ANIK reached as high as $186.3 million in Q2 2022 and fell as low as $85.8 million in Q1 2026.
• Historically, Non-Current Assets has averaged $128.9 million across 5 years, with a median of $107.3 million in 2023.
• Across the five-year window, Non-Current Assets advanced 1.03% in 2023 and plunged 44.39% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $179.6 million in 2022, then plunged by 40.24% to $107.3 million in 2023, then declined by 16.99% to $89.1 million in 2024, then dropped by 2.44% to $86.9 million in 2025, then retreated by 1.25% to $85.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $85.8 million in Q1 2026, $86.9 million in Q4 2025, and $87.8 million in Q3 2025.